These previous reports support our data significantly showing that T2DM individuals who were being treated with glibenclamide have reduced TNF-α and IL-8 while it enhances IL-6 production and M2 surface markers on primary human monocytes, leading to impair mycobacterial killing (even though some of DM individuals who were being treated with glibenclamide were also being treated with metformin in combination). Here, IL6 is linked to diabetes mellitus.